Chronic Kidney Disease (CKD) rarely makes headlines, but its impact is staggering. As kidney function declines, patients face a cascade of serious, often irreversible complications: cardiovascular disease, fluid overload, nerve damage, and eventual kidney failure requiring dialysis or transplant.
And yet, for a disease affecting more than 37 million Americans, treatment remains inconsistently managed, poorly understood by patients, and dangerously delayed.
Inside the Essence Patient Solutions network alone, nearly 2 million patients are living with uncontrolled CKD. These individuals are at high risk, and many of them don’t even know it. CKD often progresses silently, with minimal symptoms until kidney function is severely compromised.
Pharmaceutical marketers have a transformative opportunity. With the right engagement strategies, brands can do more than drive awareness. They can change the course of disease progression. Whether promoting SGLT2 inhibitors, RAAS-targeting medications, or other renal-protective therapies, pharma teams have the tools to help patients preserve kidney function and avoid catastrophic outcomes.
But to get there, we must solve the activation gap.
- Many patients aren’t getting regular eGFR or creatinine monitoring.
- Providers may miss early signs or delay initiating guideline-based therapy.
- Most importantly, patients aren’t being educated or empowered early enough to act.
Essence helps bridge this divide by identifying and activating high-risk patients through personalized education and timely provider collaboration. By leveraging real-world data and targeted messaging, we help pharma brands reach the right patients at the right moment, before it’s too late.
Improving renal outcomes means extending lives, avoiding hospitalizations, and preserving quality of life. For brand teams, CKD represents a critical opportunity to lead in an area of urgent and unmet need.
Two million patients. One clear path forward.